Navigation Links
ThromboGenics is Shortlisted for "Biotech Company of the Year" and "Licensing Deal of the Year" at Scrip Awards 2009
Date:9/11/2009

LEUVEN, Belgium, September 11 /PRNewswire-FirstCall/ --

- ThromboGenics' Significant Achievements Over the Last Year are Recognised in Nominations

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on the discovery and development of innovative treatments for eye disease, vascular disease and cancer, announced today that it has been shortlisted for both the "Biotech Company of the Year" and "Licensing Deal of the Year" awards at the Scrip Awards 2009. These nominations recognise the transformational year that ThromboGenics has had, and the progress it has made toward becoming a profitable, integrated Company focused on cutting edge ophthalmic medicines.

The Biotech Company of the Year award recognises the progress and achievement a biotech company has made within the last twelve months. During the period, ThromboGenics has started the pivotal transatlantic Phase III programme with microplasmin for back of the eye disease, signed a EUR500 million partnership deal with Roche for its novel anti-cancer antibody TB-403, and moved its novel anti-coagulant TB-402 into Phase II trials. TB-402 is another potential partnership opportunity. There are four other companies nominated in this category.

The Licensing Deal of the Year award acknowledges the achievement of a Company in signing a licensing deal that has both monetary and strategic benefits to all parties. ThromboGenics signed a major partnership deal with Roche for TB-403 under which the Company and co-development partner BioInvent received an upfront payment of EUR50 million, an additional EUR450 million in potential milestones, and double digit royalties on future product sales. There are four other licensing deals nominated in this category.

The Scrip Awards is one of the biotechnology and pharmaceutical industry's most prestigious and highly contested awards event. The event is in its fif
'/>"/>

SOURCE ThromboGenics NV
Copyright©2009 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3

Related biology technology :

1. ThromboGenics - Business Update and Interim Results for the Seven Month Period Ending 30 June 2007
2. ThromboGenics Announces Successful Completion of Technology Transfer to Bharat Biotech for Production of Novel Thrombolytic Agent
3. ThromboGenics and BioInvent Announce Successful Completion of Phase I Clinical Trial of the Anticoagulant TB-402
4. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
5. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
6. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
7. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
8. ThromboGenics Announces 2007 Full Year Results
9. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
10. ThromboGenics N.V. - Business Update
11. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... Dr. Ingrid Warmuth and Anamaria Newport, MHS, PA-C, with locations ... an Open House at their Swedesboro location, 95 Woodstown Road. ... 10 AM to 2 PM. , During the open ... be on hand to talk to people about the benefits ... cosmetic consultations. There will also be specials offered, such as ...
(Date:5/24/2013)... Israel , May 24, 2013 ... leader in embolic protection stents, announced that Alan ... and Craig Shore , the Company,s Chief ... Investor Conference on Thursday May 30, 2013 at The Pfister ... The format of the conference includes a ...
(Date:5/24/2013)... 24, 2013 Many factors impact tissues ... or efflux transporters at the blood-tissue barrier. Even when ... unbound fractions in the tissue rather than the total ... challenges is required to guide lead optimization, predict in ... species-dependent variables that may impact the likely human clinical ...
(Date:5/24/2013)... (PRWEB) May 24, 2013 Quincy ... discovery and development of calcium-binding proteins to support ... safety assessment study of apoaequorin in ... journal published for the British Industrial Biological Research ... was to investigate potential adverse effects, if any, ...
Breaking Biology Technology:InspireMD To Participate In Benchmark Investor Conference On May 30th 2InspireMD To Participate In Benchmark Investor Conference On May 30th 3InspireMD To Participate In Benchmark Investor Conference On May 30th 4DMPK for Targeted Tissue Delivery: Solutions for the Most Challenging Part of Outsourcing, New Life Science Webinar Hosted by Xtalks 2Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology 2
... premiered this week a new Mediasite ... audience on the Internet interested in multimedia presentations featuring ... presentations by users of the companys rich media software ... with other media sources slideshows and text. The site ...
... the service they are getting, a Consumer Reports survey shows. ... "dead" zones, dropped calls and more, and ended up finding ... in consumer's minds. , ,And to top it off, almost ... services. , ,Verizon came out on top in satisfaction in ...
... took place this past week at the University of Chicagos ... of the meeting was an opportunity to hear from four ... BIO meetings in different cities, as a preview to what ... of Biotechnology meeting comes to Chicago in April, 2006. , ...
Cached Biology Technology:Sonic Foundry creates search engine for 7,000 expert video presentations 2The legacy of BIO 2006, what it will be and how we need to plan for it now 2The legacy of BIO 2006, what it will be and how we need to plan for it now 3The legacy of BIO 2006, what it will be and how we need to plan for it now 4The legacy of BIO 2006, what it will be and how we need to plan for it now 5The legacy of BIO 2006, what it will be and how we need to plan for it now 6
(Date:5/22/2013)... A new, streamlined approach to genetic engineering drastically ... new genes into bacteria, the workhorses of biotechnology, ... ACS Synthetic Biology , the method paves the ... for drug development, environmental cleanup and other activities. ... or integrating, a piece of the genetic material ...
(Date:5/22/2013)... whole organism, as they may lead to life-threatening illnesses ... report how byproducts of respiration cause mispairing of subunits ... cells controls the form and function of every cell ... encoded in the linear sequence of the four subunits ... guanine (G) and thymine (T). Random changes in the ...
(Date:5/22/2013)... new details on how climate change will affect interactions ... the Journal of Animal Ecology . This knowledge, ... informing policymakers of how species are likely to be ... a growing recognition among biologists that climate change is ... this is going to have very important consequences for ...
Breaking Biology News(10 mins):DNA damage: The dark side of respiration 2UCLA life scientists present new insights on climate change and species interactions 2UCLA life scientists present new insights on climate change and species interactions 3UCLA life scientists present new insights on climate change and species interactions 4UCLA life scientists present new insights on climate change and species interactions 5
... CA--The four largest nonprofit plant science research institutions in ... of Independent Plant Research Institutes (AIPI) in an effort ... challenges facing society in a more coordinated and rapid ... Institute for Plant Research (Cornell University), The Carnegie Institution ...
... the most recent, popular supplements for athletes looking to boost ... called L-arginine. The reason for its popularity is ... "First, L-arginine is a precursor for nitric oxide that ... aid the delivery of important nutrients to working muscles and ...
... was random, regulated, double-blinded and broad-based. The drug was tested ... Type 1 diabetes a short time before joining the trial. ... Europe, Israel and South Africa. The patients in the trial ... the trial drug (DiaPep277) through a subcutaneous injection once every ...
Cached Biology News:Big boost to plant research 2Big boost to plant research 3L-arginine: Supplement tested on fit, athletic men shows no advantage 2L-arginine: Supplement tested on fit, athletic men shows no advantage 3Andromeda Biotech: A drug for type 1 diabetes 2